Functional Technologies Corp.

Functional Technologies Corp.

November 14, 2011 07:00 ET

Functional Technologies Announces Next Generation Acrylamide-Preventing Yeast Technology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 14, 2011) - Functional Technologies Corp. (TSX VENTURE:FEB) (the "Company") is pleased to report the development of a third (3rd) generation of its proprietary acrylamide-preventing (AP) yeast platform, wherein various improvements made to the Company's original underlying AP technology have enabled the yeast's capacity to degrade asparagine, the rate-limiting precursor to acrylamide, to be accelerated and elevated.

In laboratory and simulated commercial conditions, this 3rd generation enhancement is capable of yielding considerably improved rates of asparagine reduction (i.e. more than 95% reduction) in various products tested, including in commercial materials used to produce non-bread related food products. This level of reduction was achieved in various timeframes, from short up to pre-specified time periods, depending on conditions employed (e.g. yeast inoculation rates). Notably, studies have demonstrated that with the use of this 3rd generation AP technology, desired levels of asparagine reduction can be reliably achieved within end-user defined parameters and protocols. Such results can be attained within the first or second level of efficacy testing and protocol optimization. Compared to the first (1st) generation AP yeast technology, this latest achievement represents a significant advancement with respect to the timing and inoculation rates required to attain superior asparagine-reduction rates.

The results obtained to date suggests that not only does Functional Technologies' 3rd generation AP technology provide more rapid and effective reduction of acrylamide, but also adoption and integration into an end-user's pre-specified food production or processing protocols should be relatively seamless. As well, these yeasts have demonstrated the capacity for flexible adoption, such that the conditions associated with their application can be optimized to suit the end-user's requirements while maintaining effectiveness. The combined exceptional product performance and capability to optimize this performance to adapt to production requirements, reflects the body of yeast and product development knowledge that Functional Technologies' scientists have amassed.

"Functional Technologies' ability to continuously improve on existing technologies speaks to the strength of the Company's core yeast competencies, while the results obtained with this latest technology advancement points to the increasing viability for our acrylamide-mitigating platform to meet strict production requirements," said Howard Louie, chairman and CEO of Functional Technologies. "These qualities are important in maintaining or even improving the Company's position with existing and future food industry thought leaders or collaborating companies, in the joint development and potential commercialization of Functional Technologies' acrylamide-preventing yeasts."

Forward-Looking Information

This news release contains forward-looking information (within the meaning of Canadian securities legislation) about Functional Technologies Inc. and its future plans. Forward-looking information relate to future events or future performance and reflect management's expectations or beliefs regarding future events rather than historical facts, and in this news release include the statements (the "forward-looking statements") regarding: (1) the ability for the Company's yeast technologies to reduce acrylamide in novel food applications under commercial conditions; (2) the ability for the Company's yeast technologies to be adopted in a relatively seamless fashion, to suit the end-user's requirements while maintaining effectiveness; and (3) the ability of the Company to form new collaborative and/or commercial partnerships. The forward-looking statements in this news release are subject to various risks, uncertainties and other factors that could cause the Company's actual results or achievements to differ materially from those expressed in or implied by forward-looking statements. These risks, uncertainties and other factors include, without limitation, uncertainty as to the Company's ability to achieve the goals and satisfy the assumptions of management; uncertainty as to the demand for the Company's products and the Company's ability to meet such demand; and general economic factors and other factors that may be beyond the control of the Company. Forward-looking statements are based on the opinions and expectations of the Company's management at the time they are made, and the Company does not assume any obligation, beyond what is required under applicable Canadian securities legislation, to update its forward-looking statements if those opinions or expectations, or other circumstances, should change. Reference to the section entitled "Risks and Uncertainties" commencing on page 19 of the Company's management's discussion and analysis relating to the fiscal quarter ended May 31, 2011, which is available on SEDAR at

About Functional Technologies Corp.

Functional Technologies develops and commercializes proprietary, advanced yeast-based solutions to significant challenges in the food, beverage and healthcare industries. The Company's platform improves the performance of innate yeast functions, and prevents the formation of naturally occurring toxins and contaminants that either affect final product quality or are classified by the World Health Organization as probable human carcinogens. Functional Technologies' lead technologies include yeasts that prevent and reduce the formation of the foul-smelling hydrogen sulphide (H2S) and the carcinogens acrylamide and ethyl carbamate (more commonly known as urethane), by-products of food and beverage processing. These contaminants are found in many commonly consumed items, such as fermented food products and alcoholic beverages, and baked and fried foods. With a head office in Vancouver, Functional Technologies Corp. has R&D operations in Prince Edward Island and Europe, as well as a U.S. sales office in Napa Valley, California. For more information, please visit our website at


Contact Information